Medical Devices & Surgical Technology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
World Journal of Gastroenterology
Which is promising as therapeutic targets in patients with biliary tract cancer? EGFR or HER2?
November 8th, 2009
The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others. It is unknown if EGFR and HER2 are overexpressed in advanced biliary tract cancer (BTC) and therefore may serve as therapeutic targets in these cancers. A research article to be published on September 28, 2009 in the World Journal of Gastroenterology addresses this question. A research team from Germany studied EGFR and HER2 expression in biopsy samples from...
Source: Medical Devices & Surgical Technology Week (2009-11-08)
|
